Zoledronic acid-induced transient hepatotoxicity in a patient effectively treated for Paget's disease of bone.
Bisphosphonate (BP)-induced hepatotoxicity is very rare. There are only a few reports of liver injury after BP treatment, including aledronate and risedronate in postmenopausal osteoporosis patients. We describe hereby the case of a patient with Paget's disease of bone accompanied by nonalcoholic fatty liver disease (NAFLD) who developed transient hepatotoxicity after zoledronic acid (ZOL) treatment. NAFLD had been diagnosed 1 year before presentation, based on liver ultrasonography (US). One day after infusion, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and gamma-glutamyltransferase (GGT) were increased by 8.1, 6.7, and 6.7 times, respectively, compared with pretreatment values. Serum bilirubin remained normal. US revealed hepatic mild homogenous brightness without focal lesion of the liver or biliary ducts. Subsequent biochemical and serologic investigation did not reveal a specific liver or systematic disease. The patient remained asymptomatic, and ALT, AST, and GGT were normalized 7 days post-treatment. Although the mechanism by which ZOL may cause liver damage is elusive, physicians should be aware of this possible adverse effect and ZOL cautiously administered in NAFLD patients.
Polyzos
S A
SA
Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece. stergios@endo.gr
Kountouras
J
J
Anastasilakis
A D
AD
Litsas
I
I
Kita
M
M
Arsos
G
G
Moralidis
E
E
Terpos
E
E
D050071:Bone Density Conservation Agents / Q000009:adverse effects* / Q000627:therapeutic use; D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology*; D004164:Diphosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D005234:Fatty Liver / Q000150:complications; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D065626:Non-alcoholic Fatty Liver Disease; D010001:Osteitis Deformans / Q000000981:diagnostic imaging / Q000188:drug therapy*; D011877:Radionuclide Imaging; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
J Bone Miner Res. 1996 Feb;11(2):178-82
8822341
Osteoporos Int. 2008 Aug;19(8):1109-17
18504638
J Bone Miner Metab. 2008;26(6):635-41
18979164
Gastroenterol Clin Biol. 2002 Feb;26(2):179-80
11938071
Gastroenterol Hepatol. 2001 May;24(5):244-6
11412594
N Engl J Med. 2000 Aug 3;343(5):365-6
10928896
Neth J Med. 1998 Dec;53(6):271-2
9883006
Osteoporos Int. 2007 Jun;18(6):829-31
17226065
Chem Res Toxicol. 2007 Sep;20(9):1291-9
17676813
N Engl J Med. 2005 Sep 1;353(9):898-908
16135834
Curr Mol Med. 2009 Apr;9(3):299-314
19355912
Support Care Cancer. 2009 Oct;17(10):1329-30
19641941
Am J Med. 2007 Mar;120(3):e1-2
17349419
Osteoporos Int. 1999;10(2):120-2
10501791
J Dent Res. 2007 Nov;86(11):1022-33
17959891